8 Amendments of Gary TITLEY related to 2007/2257(INI)
Amendment 1 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Recognises that the sector faces a challenging future due to globalisation, technological development and the environment;
Amendment 3 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Regrets the weakness of the link between EU and national industrial policy and calls on the Commission and Member States to work to strengthen this link;
Amendment 7 #
Draft opinion
Paragraph 4
Paragraph 4
4. Recalls the importance of the initiative to establish a "law for small companies" at European level in particular as an opportunity to reduce through exemptions the burden from regulation faced by SMEs;
Amendment 8 #
Draft opinion
Paragraph 5
Paragraph 5
5. Stresses the importance of preserving the strength of European industry with the framework of competition policy, and would, iopen pmarticular,kets, and would like to see the adjustment of the European regulatory framework and the international rules and standards which apply to trade to be taken into account, so that fair competition conditions can be promoted at international level;
Amendment 9 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Welcomes the partnership groupings initiated by the Commission, such as CARS 21 and the High Level Group on Textiles; believes that these groupings are important fora for strengthening EU industrial policy;
Amendment 12 #
Draft opinion
Paragraph 6
Paragraph 6
6. Recalls that an ambitious DPIIPR policy is a key element in the competitiveness of industrial companies and particularly SMEs, and concluding a European patent litigation agreement and the reaching of an agreement on the Community patent;
Amendment 13 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Supports the Commission's ongoing programme to simplify and improve the regulatory environment and reduce administrative burdens;
Amendment 16 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Is gravely concerned about the long term future of the pharmaceutical sector and particularly the weakness of European research and development and the lack an effective single market in this sector; calls on the Commission and Member States to address this issue urgently;